RHUMBLINE ADVISERS - CUE BIOPHARMA INC ownership

CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 38 filers reported holding CUE BIOPHARMA INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of CUE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$72,238
-32.7%
31,410
+6.9%
0.00%
Q2 2023$107,280
-30.8%
29,392
-7.5%
0.00%
Q1 2022$155,000
-56.9%
31,768
-0.1%
0.00%
Q4 2021$360,000
-23.7%
31,804
-1.9%
0.00%
-100.0%
Q3 2021$472,000
+30.7%
32,414
+4.5%
0.00%
Q2 2021$361,000
-10.6%
31,014
-6.3%
0.00%
-100.0%
Q1 2021$404,000
-7.6%
33,092
-5.3%
0.00%0.0%
Q4 2020$437,000
-15.0%
34,933
+2.3%
0.00%0.0%
Q3 2020$514,000
-41.6%
34,163
-4.8%
0.00%0.0%
Q2 2020$880,000
+151.4%
35,893
+45.7%
0.00%0.0%
Q1 2020$350,000
-8.9%
24,631
+1.8%
0.00%0.0%
Q4 2019$384,000
+93.0%
24,206
+2.4%
0.00%
Q3 2019$199,000
-5.2%
23,630
+1.0%
0.00%
Q2 2019$210,000
+19.3%
23,405
+2.7%
0.00%
Q1 2019$176,000
+64.5%
22,792
-0.0%
0.00%
Q4 2018$107,000
-21.3%
22,795
+51.3%
0.00%
Q3 2018$136,000
-27.7%
15,071
-5.1%
0.00%
Q2 2018$188,00015,8750.00%
Other shareholders
CUE BIOPHARMA INC shareholders Q2 2019
NameSharesValueWeighting ↓
Prosight Management, LP 829,042$9,376,0005.61%
P.A.W. CAPITAL CORP 120,000$1,357,0001.24%
Nantahala Capital Management 2,539,700$28,724,0001.01%
Slate Path Capital LP 1,483,619$16,780,0000.88%
SANDERS MORRIS HARRIS LLC 359,113$4,416,0000.76%
APOGEM CAPITAL LLC 62,295$705,0000.46%
Robertson Stephens Wealth Management, LLC 478,500$5,411,0000.46%
Bleichroeder LP 200,000$2,262,0000.35%
ADVISORY RESEARCH INC 257,225$2,909,0000.23%
Granite Point Capital Management, L.P. 110,000$1,244,0000.21%
View complete list of CUE BIOPHARMA INC shareholders